Patents by Inventor Michael Bustin

Michael Bustin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic antitumor combination of a TLR4 ligand with other treatments
    Patent number: 11266746
    Abstract: Methods of treating cancer or reducing the incidence of relapse of a cancer in a subject comprising co-administration of Toll-like receptor (TLR) 4 ligand, such as an HMGN1 protein, and a TLR 7 or 8 ligand, and optionally an immune checkpoint inhibitor, to the subject in need of such therapy. The TLR4-mediated immune-stimulating effect is synergistically enhanced by ligands of TLR7 or 8, and the immune checkpoint inhibitor. Also described here is a nanoparticle delivery platform for the co-administration of the TLR 4 ligand and the TLR 7 or 8 ligand.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: March 8, 2022
    Assignee: The United Slates of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Joost J. Oppenheim, De Yang, Zhen Han, Joseph John Barchi, Jr., Michael Bustin
  • THERAPEUTIC ANTITUMOR COMBINATION OF A TLR4 LIGAND WITH OTHER TREATMENTS
    Publication number: 20190151466
    Abstract: Methods of treating cancer or reducing the incidence of relapse of a cancer in a subject comprising co-administration of Toll-like receptor (TLR) 4 ligand, such as an HMGN1 protein, and a TLR 7 or 8 ligand, and optionally an immune checkpoint inhibitor, to the subject in need of such therapy. The TLR4-mediated immune-stimulating effect is synergistically enhanced by ligands of TLR7 or 8, and the immune checkpoint inhibitor. Also described here is a nanoparticle delivery platform for the co-administration of the TLR 4 ligand and the TLR 7 or 8 ligand.
    Type: Application
    Filed: February 24, 2017
    Publication date: May 23, 2019
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Joost J. Oppenheim, De Yang, Zen Han, Joseph John Barchi, Michael Bustin
  • HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
    Patent number: 9567566
    Abstract: A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: February 14, 2017
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: De Yang, Joost J. Oppenheim, Michael Bustin
  • HMGN POLYPEPTIDES AS IMMUNE ENHANCERS AND HMGN ANTAGONISTS AS IMMUNE SUPPRESSANTS
    Publication number: 20160296620
    Abstract: A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.
    Type: Application
    Filed: June 23, 2016
    Publication date: October 13, 2016
    Inventors: De Yang, Joost J. Oppenheim, Michael Bustin
  • HMGN POLYPEPTIDES AS IMMUNE ENHANCERS AND HMGN ANTAGONISTS AS IMMUNE SUPPRESSANTS
    Publication number: 20120269839
    Abstract: A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.
    Type: Application
    Filed: June 26, 2012
    Publication date: October 25, 2012
    Applicant: The U.S.A. as represented by the Secretary,Depart. of Health and Human Services
    Inventors: De Yang, Joost J. Oppenheim, Michael Bustin
  • HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
    Patent number: 8227417
    Abstract: A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: July 24, 2012
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: De Yang, Joost J. Oppenheim, Michael Bustin
  • HMGN POLYPEPTIDES AS IMMUNE ENHANCERS AND HMGN ANTAGONISTS AS IMMUNE SUPPRESSANTS
    Publication number: 20100021488
    Abstract: A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbpl, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbpl, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.
    Type: Application
    Filed: July 24, 2009
    Publication date: January 28, 2010
    Applicant: The USA, as represented by the Secretary, Dept. of Health and Human Service
    Inventors: De Yang, Joost J. Oppenheim, Michael Bustin